Page last updated: 2024-09-04

liensinine and ER-Negative PR-Negative HER2-Negative Breast Cancer

liensinine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gong, Y; Li, B; Liu, Q; Liu, T; Liu, Z; Shao, C; Wang, R; Wang, X; Wu, T; Zhang, X	1

Other Studies

1 other study(ies) available for liensinine and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation. Scientific reports, 2015, Jul-29, Volume: 5 Topics: Apoptosis; Benzylisoquinolines; Cell Line, Tumor; Enzyme Activation; Female; Humans; Isoquinolines; MAP Kinase Signaling System; MCF-7 Cells; p38 Mitogen-Activated Protein Kinases; Phenols; Reactive Oxygen Species; Triple Negative Breast Neoplasms	2015

Article

Year

Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation.

Scientific reports, 2015, Jul-29, Volume: 5

Topics: Apoptosis; Benzylisoquinolines; Cell Line, Tumor; Enzyme Activation; Female; Humans; Isoquinolines; MAP Kinase Signaling System; MCF-7 Cells; p38 Mitogen-Activated Protein Kinases; Phenols; Reactive Oxygen Species; Triple Negative Breast Neoplasms

2015